Syntheses and biological evaluation of novel pseudomycin side-chain analogues. Part 2.
A series of aliphatic side-chain analogues of pseudomycin was synthesized and evaluated during the course of our side-chain SAR effort. We found that several of the pseudomycin side-chain analogues (e.g., 10) exhibited good in vitro activity against all three major fungi responsible for systemic fungal infections.
Chen
S H
SH
Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. chen_shu-hui@lilly.com
Sun
X
X
Boyer
R
R
Paschal
J
J
Zeckner
D
D
Current
W
W
Zweifel
M
M
Rodriguez
M
M
D000935:Antifungal Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D001232:Aspergillus fumigatus / Q000187:drug effects; D002176:Candida albicans / Q000187:drug effects; D003455:Cryptococcus neoformans / Q000187:drug effects; D005658:Fungi / Q000187:drug effects / Q000254:growth & development; D009682:Magnetic Resonance Spectroscopy; D008826:Microbial Sensitivity Tests; D010456:Peptides, Cyclic / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D011549:Pseudomonas / Q000737:chemistry; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D000935:Antifungal Agents; D010456:Peptides, Cyclic; C107665:pseudomycin A